Kerman Health System Workers Knowledge and AttitudesRegarding the Spontaneous Reporting System forAdverse Drug Reactions ADR reporting by health system workers
Iranian Journal of Pharmaceutical Sciences,
مجلد 5 عدد 4 (2009),
1 October 2009
,
الصفحة 249-252
https://doi.org/10.22037/ijps.v5.41231
الملخص
Adverse drug reaction (ADR) is one of the most life threatening problems, and the economic burden of ADR is considerable. The main objective of this study was to assess the attitude of the Kerman health system staff, to evaluate their knowledge of the spontaneous reporting system and to identify the reasons for low reporting rate. In this descriptive study, a Persian translated questioner was used based on standard European pharmacovigilance research group. Among 800 distributed questionnaires, 78% were filled and returned. Returned questioner (82%) indicated to have already suspected an ADR but only 4% reported it to Iranian ADR centre.The 4 major reasons for not reporting were: a) reporting process was unknown (65%),b) Iranian pharmacovigilance centre was unknown for the staff (45%), c) the yellow cards for reporting ADR were not available (30%), and d) ADR were not important (22%). We concluded that our medical staff's knowledge about ADR is little. Appropriate teaching and acceptable effort is needed to strengthen the current system and to prevent other serious ADRs.
- Adverse drug reaction
- Attitude
- Knowledge.
كيفية الاقتباس
المراجع
[2]Wasserfallen JB, Livio F, Buclin T, Tillet L, Yersin B, Biollaz J. Rate, type, and cost of adverse drug reactions in emergency department admissions.Eur J Internal Med 2001; 12: 442-7.
[3]Vasco M, Pinheiro L, Albuquer J, Lucas M,Victorino RM. Adverse drug reaction in an internal medicine department. Eur J Internal Med 2003;14: S1-S159:P403.
[4]Cunningham G, Krska J. Adverse drug reactions.In: Winfield AJ, Richards RME, (editors).Pharmaceutical Practice. London Churchill Livingstone, 1999; pp. 355-65.
[5]Gallagher LP. The potential for adverse drugreaction in elderly patients. Appl Nursing Res2001; 14: 220-4.
[6]Janaje-Munasinghe TM, Singer DRJ. Costs and prevention of adverse drug reaction. Eur J Internal Med2001; 12: 403-5.
[7]Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother2000; 34: 1373-9.
[8]Chyka PA. How many deaths occur annually from ADR in US? Am J Med2000; 109: 122-31.
[9]Boyd IW. The role of the Australian ADR advisory committee in monitoring drug safety. Toxicology 2002; 181: 99-102.
[10]Lacoste-Roussillon C, Pouyanne P, Haramburu F,Miremont G, Begaud B. Incidence of serious adverse drug reactions in general practice: Aprospective study. Clin Pharmacol Ther200; 69:458-62.
[11]WHO. Safety monitoring of medicinal products,guidelines for setting up and running a pharma-covigilance centre. WHO collaborating centrefor international drug monitoring, Uppsala,Sweden. 2000.
[12]Shalviri G, Valadkhani M, Dinarvand R. Ten years pharmacovigilance activities in Iran.Irannian J Publ Health2009; 38: 162-5.
[13]www. fda .gov/medwatch.
[14]Hasford J, Goettler M, Munter KH, Muller-Oerlighausen B. Physicians knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidem 2002; 55: 945-50.[15]Fincham JE. Pilot projects to stimulate adverse drug reaction reporting. J Clin Pharm Ther1987;12: 243-7.
[16]Robins AH, Weir M, Biersteker EM. Attitudes to adverse drug reactions and their reporting among medical practitioners. S Afr Med J 1987; 72: 131-4.
- الملخص المشاهدات: 77 الأوقات
- IJPS_Volume 5_Issue 4_Pages 249-252 (English) التنزيلات: 19 الأوقات